A Novel Self-Replicating Chimeric Lentivirus-Like Particle by Jurgens, C. K. et al.
A Novel Self-Replicating Chimeric Lentivirus-Like Particle
Christy K. Jurgens,a,b,c* Kelly R. Young,a,b,c Victoria J. Madden,d Philip R. Johnson,e and Robert E. Johnstona,b,c
Carolina Vaccine Institute,a Department of Microbiology and Immunology,b and Global Vaccines, Inc.,c Research Triangle Park, North Carolina, USA; Department of
Pathology, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, USAd; and Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USAe
Successful live attenuated vaccines mimic natural exposure to pathogens without causing disease and have been successful
against several viruses. However, safety concerns prevent the development of attenuated human immunodeficiency virus (HIV)
as a vaccine candidate. If a safe, replicating virus vaccine could be developed, it might have the potential to offer significant pro-
tection against HIV infection and disease. Described here is the development of a novel self-replicating chimeric virus vaccine
candidate that is designed to provide natural exposure to a lentivirus-like particle and to incorporate the properties of a live at-
tenuated virus vaccine without the inherent safety issues associated with attenuated lentiviruses. The genome from the alphavi-
rus Venezuelan equine encephalitis virus (VEE) was modified to express SHIV89.6P genes encoding the structural proteins Gag
and Env. Expression of Gag and Env from VEE RNA in primate cells led to the assembly of particles that morphologically and
functionally resembled lentivirus virions and that incorporated alphavirus RNA. Infection of CD4 cells with chimeric
lentivirus-like particles was specific and productive, resulting in RNA replication, expression of Gag and Env, and generation of
progeny chimeric particles. Further genome modifications designed to enhance encapsidation of the chimeric virus genome and
to express an attenuated simian immunodeficiency virus (SIV) protease for particle maturation improved the ability of chimeric
lentivirus-like particles to propagate in cell culture. This study provides proof of concept for the feasibility of creating chimeric
virus genomes that express lentivirus structural proteins and assemble into infectious particles for presentation of lentivirus
immunogens in their native and functional conformation.
The development of an effective vaccine against human immu-nodeficiency virus (HIV) remains a formidable challenge 30
years after its discovery. Significant advances in the fields of mo-
lecular biology, virology, and immunology have led to the devel-
opment of novel vaccine technologies, including plasmid DNA
vaccines, virus-like particle (VLP)-based vaccines, and recombi-
nant viral or other microbial vaccine vectors which have been used
to deliver simian immunodeficiency virus (SIV) or HIV immuno-
gens (47). The most promising design thus far has involved the
delivery of SIV or HIV genes by live, recombinant viral vectors
with or without priming the immune response with plasmid DNA
expressing the desired immunogen (18, 26, 56). Although there
has been significant success in lowering viral loads after challenge
with pathogenic SIV or simian-human immunodeficiency virus
(SHIV) and long-term control of viremia in rhesus macaques,
none of these technologies have induced complete protection
against disease much less against infection (11). For those vaccine
modalities showing the most promising immunological results in
nonhuman primate models, expanded phase II and phase III hu-
man trials testing antibody-based and T cell-based HIV-1 vaccines
have failed (29, 36). More recently, a heterologous prime-boost
strategy, combining a canarypox prime (ALVAC) followed by
protein boost (VAXGEN), provided modest and transient protec-
tion against infection shortly after vaccination; however, the vac-
cine regimen had no effect on set point viral load after acquisition,
and protection against acquisition waned as time after vaccination
increased (42). Therefore, failure to protect against infection and
disease in rigorous primate challenge models may correlate with
failure to protect against infection and disease in humans.
In nonhuman primate models to date, live attenuated SIV vac-
cines have offered the highest degree of protection against muco-
sal and systemic challenge with uncloned, pathogenic SIV isolates
(8, 22, 31, 55). Integration of the proviral DNA into the host chro-
mosome and the persistent nature of lentiviruses, combined with
their high rate of mutation and evolution, are safety concerns
precluding the continued development of live attenuated HIV for
human trials. However, if a safe, live attenuated virus vaccine
could be developed, it might have the potential to induce signifi-
cantly improved protection against HIV-1 infection. Thus, the
goal is to design a vaccine which incorporates the advantages of a
live attenuated virus vaccine without the inherent safety issues
surrounding the use of attenuated lentiviruses.
Alphaviruses from the Togaviridae family of positive-strand
RNA viruses are widely used as vectors to express heterologous
proteins, both in vitro and in vivo (39, 50), and have been used as
vaccine vectors to deliver SIV and HIV antigens that are immuno-
genic (1, 3, 4, 10, 34, 35). The 5= end of the genome encodes four
nonstructural proteins which form the replicase complex for tran-
scription and replication of the RNA genome. The alphavirus
structural proteins are expressed from a subgenomic RNA tran-
scribed from the 26S subgenomic promoter immediately down-
stream of the replicase genes. Replacement of the alphavirus struc-
tural genes with a gene of interest downstream from the internal
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26S subgenomic mRNA promoter results in high levels of heter-
ologous protein expression. A second functional 26S promoter
and associated heterologous gene may be inserted downstream
from the first heterologous gene cassette, driving the expression of
an additional gene insert (9, 40).
Assembly of lentiviral particles is primarily mediated by the
viral protein Gag. In the absence of other viral proteins, Gag pro-
teins multimerize via dimerization domains located in the C ter-
minus of capsid and self-assemble into immature particles that are
competent to bud from the cell. Assembly requires RNA, and Gag
particles nonspecifically acquire RNA during the assembly process
in the absence of lentivirus genomic RNA (2, 14). Expression of
Gag from alphavirus replicon RNA is sufficient for assembly of
Gag particles (5). The lentivirus accessory genes are not required
for optimal lentiviral structural gene expression as all of the genes
and cis-acting sequences required for alphavirus RNA transcrip-
tion and replication are contained in the replicon genome, and
alphavirus replication is exclusively cytoplasmic with no DNA in-
termediate. Also, it has been shown that HIV Gag expression from
the positive-strand RNA virus Japanese encephalitis virus results
in efficient Gag VLP assembly in the absence of the HIV accessory
proteins Rev and Rev-responsive element (RRE) (58).
The design of the chimeric virus vaccine prototype described
here utilizes the RNA genome from the alphavirus Venezuelan
equine encephalitis virus (VEE) encoding a subset of lentivirus
gene products sufficient for self-assembly of lentivirus-like parti-
cles that present Gag and Env in their native conformations. If the
replicon RNA were packaged into such chimeric particles and if
the replicon genome were then released into the cell cytoplasm
after entry of the chimeric particles into susceptible cells, then the
chimeric particles could potentially self-propagate and function as
a live virus vaccine. The vaccine would induce innate immune
responses and would be cleared from the body after sufficient
induction of adaptive humoral and cellular responses to the len-
tivirus immunogens. Using this system, the inherent safety limi-
tations of live attenuated lentivirus vaccines may be overcome,
based on the following observations. (i) Alphaviruses replicate
exclusively in the cytoplasm of the infected cell. There is no DNA
intermediate, no nuclear replicative step, and hence no integra-
tion into the host chromosome. (ii) Alphaviruses, particularly
VEE, are sensitive to interferon, and attenuating mutations to in-
crease interferon sensitivity can be engineered into the genome to
limit its replication further (54). Since there is no integration into
the host genome and replication is self-limiting, vaccination
should not lead to persistent or chronic infection.
This design, in theory, conserves the best aspects of a live at-
tenuated virus vaccine by presenting the major lentivirus antigens
in native form to elicit a broad, balanced immune response while
overcoming many of the inherent safety issues associated with
attenuated lentiviruses as vaccines. The prototype chimeric virus
vaccine candidate developed here contains a VEE-SHIV89.6P chi-
meric virus genome and SHIV89.6P gag, pro, and env genes, uti-
lizes the SHIV89.6P coreceptors for cell entry, and can be propa-
gated by serial passage in cell culture.
MATERIALS AND METHODS
Cells. Vero E6 cells (ATCC CRL 1586) were maintained in Dulbecco’s
modified Eagle’s medium-F12 (DMEM-F12) containing 10% fetal bovine
serum and 1% penicillin and streptomycin and supplemented with 0.29
g/ml of L-glutamine. Baby hamster kidney cells (BHK) cells (ATCC
CCL10) were maintained in alpha minimal essential medium (-MEM)
containing 10% donor calf serum, 10% tryptose phosphate broth, and 1%
penicillin and streptomycin, supplemented with 0.29 g/ml L-glutamine.
For electroporation, BHK cells were cultured in 10% fetal bovine serum.
NIH 3T3 cells (ATCC CRL 1658) and 3T3 cell lines expressing CD4,
CCR5, and CXCR4 (NIH AIDS Research and Reference Program
[NARRP] 3947 and 3948) were maintained in DMEM containing 10%
fetal bovine serum and 1% penicillin and streptomycin, supplemented
with 0.29 g/ml of L-glutamine. The NIH 3T3.CD4.CCR5 cell line was
also supplemented with 3 g/ml puromycin. U87.CD4.CCR5 and
U87.CD4.CXCR4 cells (NARRP 4035 and 4036) were maintained in
DMEM containing 15% fetal bovine serum and 1% penicillin and strep-
tomycin, supplemented with 0.29 g/ml of L-glutamine, 1 g/ml of pu-
romycin, and 300 g/ml of G418.
Plasmids expressing VEE replicon RNA and chimeric viral genomes.
(i) Construction of VEE replicon plasmids expressing SHIV89.6P Gag,
GagPR, and Env(gp160). Recombinant Venezuelan equine encephalitis
virus (VEE) replicon plasmids were constructed using standard molecular
biology techniques. Coding sequences of Gag (nucleotides 536 to 2068),
Gag-Pro (GagPR; nucleotides 536 to 2361), gp160 Env (nucleotides 6339
to 8948), and gp160 Env with a truncated cytoplasmic tail (EnvCT;
nucleotides 6339 to 8493) were PCR amplified from the SHIV89.6P KB9
molecular clone (GenBank accession numberU89134). The 5= primer
contained 26S subgenomic promoter sequences, and the 3= primer con-
tained a stop codon and an AscI site for cloning into VEE replicon plasmid
pVR21 by overlap extension PCR (19). The carboxy terminus of NSP4 and
26S promoter sequences (VEE nucleotides 6197 to 7561) were PCR am-
plified and used in an overlap extension PCR with the fragment contain-
ing the SHIV89.6P structural gene (either gag or env) with the 26S pro-
moter to obtain a PCR fragment that contained the carboxyl terminus of
NSP4, the complete VEE 26S subgenomic promoter, the SHIV89.6P
structural gene, and an AscI restriction site. This was placed into PCR
cloning vector Zero Blunt (Invitrogen) and sequenced. An attenuating
mutation in the active site of protease, from alanine at position 28 to
serine, was introduced by site-directed mutagenesis. SwaI and AscI were
used to remove the 26S subgenomic promoter and SHIV89.6P structural
genes, and the fragment was placed into VEE replicon plasmid pVR21 also
digested with SwaI and AscI. To construct double-promoter replicon
plasmids, pVR21 SHIV89.6P Gag and pVR21 SHIV89.6P Env were di-
gested with SwaI and NotI to isolate the 26S promoter and the associated
gene. The 26S-Gag fragment was ligated into pVR21 SHIV89.6P Env di-
gested with PmeI and NotI to create the double-promoter replicon plas-
mid pVR100 SHIV89.6P Env-Gag. The 26S-Env fragment was ligated into
pVR21 SHIV89.6P Gag, GagPR, or GagPR(A28S) digested with PmeI and
NotI to create pVR100 SHIV89.6P Gag-Env, GagPR-Env, and
GagPR(A28S)-Env. Positive clones were identified by restriction diagnos-
tics and were verified by sequencing.
(ii) Construction of VEE replicon plasmids expressing SHIV89.6P
GagPR(A28S)NCVEE Csub-Env. The VEE capsid fragment consisting
of amino acids 75 to 132 [VEE C(75–132)] was molecularly cloned to
replace the nucleocapsid (NC) region of SIV Gag (GagNCVEE Csub).
The VEE C fragment was synthetically produced (Biobasic, Amherst, NY)
to include the sequence between EcoNI and AscI incorporating the VEE
C(75-132) region within the proteolytic cleavage sites for p2 NC (CCTT
TTGCAGCA2GCCCAACAG) and NC2p1 (AGACAGGCGGT2TTTTTA
GGC) (protease cleavage site denoted by the down arrow). The VEE C
fragment was digested with EcoNI and AscI and cloned into pVR21 Gag to
produce replicon plasmid pVR21 GagNCVEE Csub. pVR21
GagPR(A28S) was then digested with PpuMI and AscI and ligated into
pVR21 GagNCVEE Csub digested with PpuMI and AscI to construct
replicon plasmid pVR21 GagPR(A28S)NCVEE Csub. Double-
promoter replicon plasmid pVR100 was constructed by digesting pVR21
Env with SwaI and NotI and ligating the fragment into pVR21
GagPRNCVEE Csub or pVR21 GagPR(A28S)NCVEE Csub cut
with PmeI and NotI as described above to create pVR100
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GagPR(A28S)NCVEE Csub-Env. Positive clones were identified by re-
striction diagnostics and were verified by sequencing.
RNA transfection. NotI-linearized VEE replicon plasmids encoding
SHIV89.6P Gag, Env, Gag-Env, or Env-Gag and their modified derivatives
were used as templates for the synthesis of capped VEE replicon RNAs using
an mMessage Machine T7 kit (Ambion). Subconfluent Vero or BHK cells
were harvested and prepared for electroporation. Cells were pelleted by cen-
trifugation (at 800  g for 10 min), washed with RNase-free phosphate-
buffered saline (PBS; Accugene), and resuspended to 1.5  107 cells/ml in
RNase-free PBS. Fifty micrograms of in vitro synthesized replicon RNA was
transfected into Vero or BHK cells by electroporation of 800 l of resus-
pended cells using five electrical pulses of 450 V (Vero) or three electrical
pulses of 850 V (BHK) at 25 F with a Bio-Rad gene pulser II electroporator
and 0.4-cm-gap gene pulser cuvettes (Bio-Rad). Transfected BHK cells were
placed into 75-cm2 flasks containing complete medium, and transfected Vero
cells were placed into 175-cm2 flasks containing either complete medium or
virus production serum-free medium (VP-SFM; Invitrogen) supplemented
with 0.29 g/ml of L-glutamine. Cells were incubated for 24 to 28 h at 37°C in
5% CO2.
Production and harvesting of chimeric lentivirus-like particles. Su-
pernatants from Vero cells or BHK cells transfected with SHIV89.6P Gag,
Env, Gag-Env, or Env-Gag replicon RNA and their modified derivatives
were clarified of cell debris by centrifugation at 12,000  g for 30 min at
4°C or at 3,000  g for 15 min at 4°C. Supernatants were filtered through
a 0.45-m-pore-size filter and concentrated by ultracentrifugation at
72,000  g for 4.5 h at 4°C through a 20% sucrose or OptiPrep (Accurate
Chemical & Scientific Corporation) cushion. Pellets were resuspended
overnight in 250 l to 500 l of PBS at 4°C. Alternatively, particles were
concentrated to 1 ml using Amicon Centriplus YM-100 centrifugal con-
centrators (Millipore) at 3,000  g at 4°C. Particle production was as-
sessed by determining the p27 content using a commercially available
enzyme-linked immunosorbent assay (ELISA) kit (Zeptometrix) or by
semiquantitative Western blotting. Supernatants from cells transfected
with SHIV89.6P Env RNA served as controls for infection mediated by
Env microvesicles.
For density gradient analysis, concentrated supernatants were layered
onto a 10% to 50% continuous OptiPrep gradient, and the particles were
banded by ultracentrifugation at 72,000  g for 15 h at 4°C. One-milliliter
fractions were collected starting from the bottom of the gradient using a
peristaltic pump (VWR brand mini-pump; variable flow). The density of
each fraction was determined, and the protein content was analyzed by
Western blotting, probing with anti-SIVmac251-infected monkey sera
(NARRP 2773).
Production of VRP. Preparation of VEE replicon particles (VRP) has
been previously described (38). Briefly, in vitro transcribed replicon RNA
expressing SHIV89.6P Gag, SHIV89.6P Env, or a replicon RNA lacking a
transgene (null VRP) (49) and two defective helper RNAs expressing VEE
capsid and VEE glycoproteins (V3000) were transfected into BHK cells.
Particles produced in this way contain the replicon RNA packaged in the
VEE capsid and glycoproteins. VRP-containing supernatants were har-
vested at 24 h postelectroporation, clarified, and concentrated through
20% sucrose as described above. VRP titers were determined by indirect
immunofluorescence staining using mouse serum containing antibody
against the VEE nonstructural proteins. VRP-expressing Env are desig-
nated Env-VRP, VRP-expressing Gag are designated Gag-VRP, and VRP
lacking a transgene are designated null-VRP.
Western blot analysis of SHIV89.6P structural genes. Transfected
Vero cells harvested at 24 h postelectroporation were lysed in NP-40 lysis
buffer (50 mM Tris, pH 7.2, 170 mM NaCl, 15 mM EDTA, 0.2% NP-40,
containing a protease inhibitor cocktail of phenylmethylsulfonyl fluoride
[PMSF], pepstatin, leupeptin, aprotinin, and anti-pain). Lysates were
clarified of nuclei and debris by centrifugation at 13,000 rpm for 5 min at
4°C. A portion of cell lysate or pelleted supernatant was treated with pep-
tide N-glycosidase F (PNGase F; New England BioLabs). Proteins were
denatured for 10 min at 100°C in denaturation buffer. The reaction mix-
ture was adjusted to 1 in G7 buffer and 1% NP-40 upon the addition of
PNGase F and incubated for 2 h at 37°C. Treated and untreated cell lysates
and concentrated supernatants were separated by 8% or 10% SDS-PAGE
and transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-
Rad) by semidry blotting. The membrane was blocked overnight in Tris-
buffered saline containing 0.1% Tween 20 (TBS-T) and 5% dry milk or
ECL Block (Amersham). SHIV89.6P antigens were detected by probing
the membrane with either sera from SHIV89.6P-infected monkeys (gen-
erously provided by David Montefiore, Duke University, Durham, NC),
diluted 1:1,000, or sera from SIVmac251-infected monkeys (NARRP
2773), diluted 1:1,000, followed by horseradish peroxidase (HRP)-linked
anti-monkey IgG (Sigma) secondary antibody at a 1:5,000 dilution.
SHIV89.6P envelope was detected with either HIV-Ig (NARRP 3957),
HIV-1 gp120 monoclonal 2G12 (NARRP 1476), or HIV gp41 monoclonal
antibodies 2F5 and 4E10 (NARRP 1475 and 10091) at 1:10,000, followed
by HRP-linked anti-human IgG (Vector Labs) secondary antibody at a
1:20,000 dilution. Immunoreactive proteins were detected using an en-
hanced chemiluminescence system (ECL; Amersham Biosciences).
Immunoprecipitation of chimeric lentivirus-like particles with
anti-HIV gp120 IgG1 b12. Concentrated supernatants from cells mock
transfected or transfected with SHIV89.6P Gag, Gag-Env, or Env-Gag
replicon RNA were incubated with naïve monkey sera and protein
A-Sepharose CL-4B beads (Sigma) for 3 h at 4°C with agitation. Beads
were pelleted by centrifugation at 15,000  g for 5 min at 4°C, and the
supernatants were transferred to a new tube containing anti-HIV gp120
antibody IgG1 b12 (NARRP 2640) or anti-hemagglutinin (HA) monkey
serum as an irrelevant antibody control. After 3 h of incubation at 4°C
with agitation, the supernatants were transferred to a new tube containing
protein A-Sepharose beads and incubated overnight at 4°C with agitation.
Beads were pelleted by centrifugation and washed three times with NP-40
lysis buffer and once with 50 mM Tris-HCl, pH 7.6. Pelleted beads were
resuspended in 30 l of 2 SDS Laemmli sample buffer. The immuno-
precipitated proteins were separated by 10% SDS-PAGE and transferred
to a PVDF membrane (Bio-Rad) by semidry blotting. SHIV89.6P Gag was
detected by probing the membrane with anti-Gag monoclonal antibody
KK64 (NARRP 2320) diluted 1:1,000, followed by HRP-linked anti-
mouse IgG (Amersham) secondary antibody at a 1:5,000 dilution and
detected using ECL (Amersham).
Transmission electron microscopy (TEM). Vero and NIH
3T3.CD4.CCR5 cells grown and treated on standard tissue culture plates
were processed in situ. The cell monolayers were rinsed briefly with
serum-free medium and fixed with 4% glutaraldehyde in 0.15 M sodium
phosphate buffer, pH 7.4, for several hours to overnight. Following three
rinses with phosphate buffer, the monolayers were postfixed for 1 h in a
mixture of 1% osmium tetroxide and 1.25% potassium ferricyanide in
0.15 M sodium phosphate buffer. The cells were rinsed in deionized water
and dehydrated through increasing concentrations of ethanol (30%, 50%,
75%, 100%, and 100%; 5 min each). Cells were infiltrated with two
changes of Polybed 812 epoxy resin (1A:2B formulation; Polysciences,
Inc., Warrington, PA) for several hours each change. The plates were
polymerized overnight (24 h) at 60°C, and the embedding capsules were
separated from the plates prior to sectioning. Ultrathin sections (70 nm)
were cut using a Diatome diamond knife; sections were mounted on 200-
mesh copper grids and stained with 4% aqueous uranyl acetate for 15 min,
followed by Reynolds’ lead citrate for 7 min. Sections were observed and
photographed using a LEO EM910 transmission electron microscope at
80 kV (LEO Electron Microscopy, Thornwood, NY).
Immunoelectron microscopy. Vero cells were grown and treated on
Nunc glass chamber slides. 3T3.CD4.CCR5 cells were grown and treated
on Nunc 13-mm round Thermanox coverslips. After samples were rinsed
with serum-free medium, the cells were fixed with 2% paraformaldehyde–
0.5% glutaraldehyde in 0.15 M sodium phosphate, pH 7.4, for several
hours. Following glutaraldehyde and paraformaldehyde fixation, the
samples were rinsed three times with sodium phosphate buffer followed
by 10 min in 30% ethanol, 50% ethanol, and an en bloc stain with 2%
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uranyl acetate in 50% ethanol for 15 min. The cells were rinsed with 50%
ethanol and dehydrated with increasing concentrations of ethanol (75%,
90%, 100%, and 100%). The slides/coverslips were infiltrated overnight in
LR white resin (hard grade; Ted Pella, Inc., Redding, CA) at 4°C. Follow-
ing a change with fresh resin, the chamber slides/coverslips were polym-
erized at 55°C overnight (24 h).
For the infected NIH 3T3.CD4.CCR5 cells, the cell monolayers con-
taining syncytia were specifically embedded in resin. The embedded cells
were separated from the glass slide, and 80-nm ultrathin sections were cut
parallel to the substrate using a Diatome diamond knife. The sections were
mounted on 300-mesh nickel grids and were stained by floating the grids,
section side down, on 20-l droplets of the reagents. All sections were
blocked before antibody exposure for 20 min in Aurion Goat Gold Con-
jugate Blocking Solution (catalog number 25596; Electron Microscopy
Sciences, Inc., Fort Washington, PA). The grids were incubated for 90 min
at room temperature in a 1:100 dilution of primary mouse anti-Gag
monoclonal antibody KK59 (NARRP 2320) and a 1:50 dilution of human
anti-HIV gp120 antibody IgG1 b12 (NARRP 2640) in 50 mM Tris-
buffered saline with 0.1% cold water fish skin gelatin and 0.01% Tween 20,
pH 7.6 (TBSFT). A negative control with normal mouse immunoglobu-
lins was performed concurrently. Following six brief rinses in TBSFT, the
sections were incubated for 2 h at room temperature in the secondary
antibody, a 1:50 dilution of goat anti-mouse antibody conjugated to 5-nm
colloidal gold beads or a 1:50 dilution of biotinylated goat anti-human
antibody in TBSFT. Sections were rinsed in TBSFT and incubated with
anti-biotin conjugated to 20-nm colloidal gold beads for 2 h. After sam-
ples were rinsed with TBSFT, the immunogold-stained grids were con-
trasted with 4% aqueous uranyl acetate for 10 min. Sections were observed
and photographed using an LEO EM910 transmission electron micro-
scope at 80 kV.
Detection of viral RNAs incorporated into chimeric lentivirus-like
particles by TaqMan real-time PCR. Particle preparations produced in
Vero cells and concentrated by pelleting through 20% OptiPrep were
incubated with 25 U/ml of Benzonase nuclease for 5 min at room temper-
ature. Nuclease was inactivated with 150 mM NaCl, and the particle prep-
arations were serially diluted 10-fold, in duplicate. Encapsidated RNA was
extracted using a MagMax Viral RNA Isolation Kit (Ambion) per the
manufacturer’s instructions and was subsequently treated with RNase-
free DNase (2 U of Turbo DNA-free DNase; Ambion).
Viral genomic and subgenomic RNAs were detected by TaqMan real-
time PCR. Primer sets and 5= 6-carboxyfluorescein (FAM) reporter dye
and 3= 6-carboxytetramethylrhodamine (TAMRA) quencher probes for
the detection of sequences in VEE NSP1 (forward primer, 5=-GCCTGTA
TGGGAAGCCTTCA; reverse primer, 5=-TCTGTCACTTTGCAGCACA
AGAAT; probe, 5=-56-FAM-CCTCGCGGTGCATCGTAGCAGC-36-
TAMSp), SIVmac239 Gag (forward primer, 5=-CAAGCGGCTAT
GCAGATTATCA; reverse primer, 5=-TGGTTGTGGGTGCTGCAA;
probe, 5=-56-FAM-AGATATTATAAACGAGGAGGCTGCAGATTGGG
A-36-TAMSp), and SHIV89.6P Env (forward primer, 5=-AGCTGTGTT
CCTTGGGTTCTTG; reverse primer, 5=-CTGTACCGTCAGCGTCAC
TGA; probe, 5=-56-FAM-CAGCAGGAAGCACTATGGGCGCAG-36-TA
MSp) were designed using PCR Express, version 2.0 (Applied
Biosystems). RNA transcripts from pVR100 SHIV89.6P Gag-Env were
DNase treated, quantitated by spectrophotometry, and diluted 15-fold, in
duplicate, to generate a standard curve starting at 9  106 genome equiv-
alents and ending at a limit of detection of 200 genome equivalents. Five
microliters of RNA standard or extracted RNA was added to one-step
reverse transcription-PCR (RT-PCR) mixtures containing TaqMan One
Step RT-PCR Master Mix Reagents (Applied Biosystems), 900 nM for-
ward and reverse primer, and 250 nM probe in Microamp optical 96-well
reaction plates (Applied Biosystems). RNA was detected using Applied
Biosystems real-time PCR using the default thermal cycling conditions for
one-step RT-PCR: 48°C for 30 min, 50°C for 2 min, 95°C for 10 min, and
40 cycles of denaturation at 95°C for 15 s followed by annealing and
extension at 68°C for 1 min. The data were collected and analyzed using
Sequence Detection, version 1.2.3, software (7000 Systems SDS Software
RQ study application; Applied Biosystems).
To account for nonspecific background, raw values obtained for con-
trol reactions without reverse transcriptase were subtracted from the val-
ues obtained in the presence of reverse transcriptase. A replicon RNA
standard was measured with each primer-probe set to generate a standard
curve for each primer-probe set used to determine the amount of genomic
and subgenomic RNA in particle preparations. The number of RNA ge-
nomes/ml was determined by averaging values obtained for two or three
dilutions of RNA extracted from particles and normalized to the p27
content of the particle preparation. The amount of genomic RNA present
in particle preparations was detected using a primer probe set specific for
the NSP1 region of the viral genome. To determine the amount of sub-
genomic RNA from the 5=-most 26S subgenomic promoter (subgenome
1), the amount of genomic RNA (value obtained with the NSP1 primer/
probe set) was subtracted from the value obtained with the Gag primer/
probe set for Gag-Env or the value obtained with the Env primer/probe set
for Env-Gag. To determine the amount of subgenomic RNA from the
3=-most 26S subgenomic promoter (subgenome 2), the value for genomic
RNA and the amount of subgenomic RNA 1 were subtracted from the
value obtained for subgenome 2 (value obtained with the Env primer/
probe set for Gag-Env or the value with the Gag primer/probe set for
Env-Gag). The values for genomes, subgenome 1, and subgenome 2 for
three independent experiments were averaged, and the standard error of
the mean was calculated.
Infection of cell lines with chimeric lentivirus-like particles and
Env-VRP. NIH 3T3, 3T3.CD4.CCR5, and 3T3.CD4.CXCR4 cells were
mock infected, infected with undiluted Gag-Env or Env-Gag chimeric
particles, or infected with Env-VRP at a multiplicity of infection (MOI) of
0.1. Eighteen hours postinfection, the cells were rinsed with PBS and fixed
with 2% paraformaldehyde. Gene expression was detected by indirect
immunofluorescence. Infected cells were rehydrated with diluent (1
PBS, 1% donor calf serum [DCS], Ca2, Mg2, 0.1% normal horse serum,
and 0.1% saponin) and blocked with diluent containing 5% normal horse
serum. The cells were incubated for 1 h at room temperature with either
(i) sera from mice infected with null-VRP plus ovalbumin (OVA) to de-
tect VEE nonstructural protein expression, (ii) sera from mice infected
with Gag-VRP to detect Gag expression, or (iii) anti-gp120 antibody b12
to detect Env expression. The cells were then washed three times with
diluent. Cells were incubated with biotinylated anti-mouse IgG or with
biotinylated anti-human IgG for 1 h, washed three times with diluent,
incubated with Alexa Fluor 594-streptavidin conjugate (Invitrogen) for
30 min, and washed three times with diluent. Cells containing VEE non-
structural proteins and SHIV89.6P structural proteins were visualized by
fluorescence microscopy and photographed.
Titration of chimeric lentivirus-like particle preparations. NIH
3T3.CD4.CCR5/CXCR4 or U87.CD4.CCR5/CXCR4 cell monolayers in
48-well dishes were infected with 2-fold dilutions of filtered, unconcen-
trated supernatants containing chimeric particles or supernatants con-
taining Env microvesicles produced in cells transfected with Env-
expressing replicon RNA in the absence of Gag. At 24 h postinfection, cell
monolayers were fixed with methanol and acetone. Syncytia were detected
by immunostaining with HIV-IG (NARRP 3957) and visualized using a
Vectastain ABC kit and VIP substrate (Vector Laboratories). Syncytia
were enumerated as plaques, and titers were determined as in a standard
plaque assay. Alternatively, U87.CD4.CXCR4 cells in eight-well glass
slides were either mock infected, infected with Env-VRP, treated with
undiluted Env microvesicle preparation (Env MV), or infected with 10-
fold serial dilutions of concentrated chimeric lentivirus-like particle prepara-
tions. At 10 to 12 h postinfection, cells were fixed in methanol for 5 min and
air dried. The cells were permeabilized in 1 TBS, 3% bovine serum albumin
(BSA), 0.1% Triton X-100, and 1% normal goat serum and blocked with 1
PBS, 5% BSA, and 5% normal goat serum. Cells were then stained with sera
from mice infected with null-VRP plus OVA, and positive syncytia were de-
tected by indirect immunofluorescence and enumerated as described above.
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For 50% tissue culture infective dose (TCID50) determination,
U87.CD4.CXCR4 cells were infected with 2-fold serial dilutions of parti-
cle preparations. The cells were fixed in methanol, and syncytia were de-
tected by indirect immunofluorescence as described above. Cytopathic
effect (CPE) was scored by syncytium formation, and the TCID50 value
was determined by the method of Reed and Muench (41).
Serial passage and propagation of chimeric lentivirus-like particles.
NIH 3T3.CD4.CCR5 cells were infected with 1  102 IU of chimeric
particles for 1 h at 37°C with 5% CO2. After infection, inoculum was
removed, cells were washed three times with 1 PBS, fresh medium was
added, and cells were incubated for 48 h at 37°C in 5% CO2. At 48 h
postinfection, the viral supernatants were clarified by centrifugation at
3,000 rpm for 15 min, followed by filtration through a 0.22-m-pore-size
filter. Viral titers were determined on NIH 3T3.CD4.CCR5 cells as de-
scribed above. A fraction of the viral supernatant was used as the inocu-
lum for the next passage. The dilution of the viral supernatants was mod-
ified based on the number of syncytia seen at the conclusion of each viral
passage: a 1:10 dilution was used for infection of passages 2 and 3, and a
1:100 dilution was used for infection of passage 4 and passage 5 to main-
tain passages at low MOIs.
To measure the growth rate of chimeric lentivirus-like particles, NIH
3T3.CD4.CCR5 cells were infected with 1  102 IU of chimeric particles
for 1 h at 37°C in 5% CO2. After 1 h, the inoculum was removed, cells were
washed three times with 1 PBS, and fresh medium was added to each
flask. Samples were taken at 12-h intervals for 72 h starting immediately
after infection (0 h postinfection [hpi]), and the titer of progeny virions
was determined on NIH 3T3.CD4.CCR5 cells as described above.
RESULTS
We hypothesized that if the HIV structural genes gag and env were
expressed from VEE replicon RNA, they would self-assemble into
immature particles that presented both Gag and Env in their na-
tive conformations. If the chimeric viral RNA was packaged into
the particles and if that genome was then released after entry of the
particles into susceptible cells, then the particles containing chi-
meric viral RNA could potentially self-propagate and function as
an attenuated virus vaccine (Fig. 1). To determine if such a chi-
meric lentivirus-like particle could be created as a potential live
attenuated virus vaccine candidate, a prototype VEE-SHIV89.6P
chimeric virus was created.
Expression of SHIV89.6P structural genes gag and env from
VEE RNA. An established reverse genetics system to modify VEE
replicon RNA was used to express the SHIV89.6P structural genes
gag and env in place of the VEE structural genes, thus creating
chimeric VEE-SHIV viral genomes (Fig. 1A). Two versions of the
virus genome were constructed, differing in the position of gag
and env cassettes since expression from the 3=-most 26S promoter
is higher than expression from the 5=-most 26S promoter (9, 40).
After transfection of genomic RNA into Vero cells, Gag and Env
were expressed to high levels, and particles were assembled and
released into the cell culture supernatant (Fig. 1B and 2A; see Fig.
S1B in the supplemental material). In the cell lysates, Env ap-
peared as a doublet corresponding to gp160 and gp120. A band
corresponding to gp41 was also present (Fig. 2A; see Fig. S1 and S2).
After treatment with the amidase N-glycosidase F (PNGase F), bands
corresponding to the size of deglycosylated gp160, gp120, and gp41
appeared, supporting the conclusion that the bands migrating at 160,
120, and 40 kDa are Env and that gp160 is cleaved into gp120 and
gp41 although cleavage was not complete (Fig. 2A; see Fig. S2 and S3).
Env was not usually detected in the concentrated supernatants by
Western blotting except in a few particle preparations, although a
very faint band corresponding in size to gp120 was detected in con-
centrated supernatants upon overexposure of the membrane (Fig.
2A; see Fig. S1). This is consistent with low incorporation of Env into
lentivirus virions (7, 59).
Gag expression was higher from Env-Gag RNA than from Gag-
Env RNA, and Env expression was higher from Gag-Env RNA
FIG 1 Propagation-competent chimeric virus vaccine. (A) Schematic of chimeric double-promoter VEE-SHIV genomes designed to express the SHIV89.6P
structural genes gag and env. (B) After transfection of double-promoter RNA into Vero cells, Gag and Env are expressed to high levels from the 26S subgenomic
promoters and assemble into lentivirus-like particles that package the double-promoter VEE-SHIV RNA and are released into the cell culture supernatant. (C)
Cells that express CD4 and coreceptors are susceptible to infection with the lentivirus-like particles, resulting in uncoating, RNA replication, assembly of progeny
chimeric particles, and virus propagation.
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than from Env-Gag RNA, consistent with published observations
regarding gene placement in alphavirus double-promoter RNAs
(40). These observations were confirmed by measuring the
amount of Gag present in Gag-Env and Env-Gag particle prepa-
rations by p27 ELISA (data not shown). Gag and Env expressed to
similar levels and assembled and released similar amounts of
lentivirus-like particles from Vero and BHK cells. Gag and Env
were also expressed and assembled and released from 3T3 (mu-
rine) cells although particle production was slightly reduced (see
Fig. S1 in the supplemental material). Partially purified particles
produced in Vero cells sedimented at a density of 1.13 to 1.18 g/ml
in continuous OptiPrep gradients, similar to lentivirus particles in
density and heterogeneity (Fig. 2B). Peak fractions were pooled
and assessed for infectivity as described below. These results sug-
gest that lentivirus-like particles are assembled and released after
expression of Gag and Env from double-promoter VEE replicon
RNA in rodent and primate cells.
Since Env was not usually detected in partially purified super-
natants from Vero cells transfected with Gag-Env or Env-Gag
RNA by Western blotting, Env incorporation was assessed by im-
munoprecipitating partially purified particle preparations with an
antibody against gp120 and detecting Gag by Western blotting. As
negative controls, Gag VLPs produced from VEE replicon RNA
expressing Gag in the absence of Env were used, and an irrelevant
antibody directed against influenza virus hemagglutinin (HA)
also was included. Antibodies against Env gp120 specifically im-
munoprecipitated particles that contained both Gag and Env (Fig.
2C, lanes 6 and 8), but particles were not immunoprecipitated
with the negative-control antibody directed against influenza vi-
rus HA (lanes 5 and 7). Gag VLPs, which did not contain Env, were
not immunoprecipitated by either anti-gp120 or anti-HA (lanes 3
and 4). These results suggest that Env was present on the particles
but at a level insufficient to be readily detected by Western blot-
ting. Since Env is expressed to higher levels from Gag-Env RNA
than from Env-Gag RNA, more particles containing Env spikes
may be present in virus preparations from cells expressing Gag-
Env than Env-Gag, and this may be reflected in the increased
amount of Gag detected in the Gag-Env particle preparation (lane
6 compared to lane 8).
To improve the incorporation of Env into chimeric lentivirus-
like particles, the cytoplasmic tail was truncated at amino acid 718,
two amino acids after the transmembrane domain of gp41. The
molecular masses of gp120 and gp41 after truncation of the cyto-
plasmic tail were expected to be approximately 105 and 25 kDa,
respectively. Chimeric lentivirus-like particles were produced and
partially purified as described in Materials and Methods, and the
incorporation of Env into the particles was determined by West-
ern blotting using monoclonal antibodies 2F5 and 4E10. As pre-
viously observed in Fig. 1, Env was not detected in Gag-Env or
Env-Gag particle preparations. Env was readily detected in Gag-
EnvCT or EnvCT-Gag particle preparations by Western blot-
ting, suggesting that the truncation significantly improved incor-
FIG 2 Expression of SHIV89.6P Gag and Env from VEE replicon RNA in primate cells. (A) Vero cells were mock transfected, transfected with Gag-Env RNA,
or transfected with Env-Gag RNA. At 24 h posttransfection, cell lysates were prepared, and cell culture supernatants were clarified and concentrated through a
20% sucrose cushion. A portion of cell lysate and concentrated supernatant were treated with PNGase F. Treated and untreated samples were separated by 10%
SDS-PAGE, and SHIV antigens were detected by Western blotting using anti-SHIV monkey sera. (B) OptiPrep density equilibrium analysis of lentivirus-like
particles produced in Vero cells. At 24 h posttransfection of Vero cells with Gag-Env or Env-Gag replicon RNA, supernatants were harvested, clarified,
concentrated, and layered onto 10 to 50% OptiPrep gradients. Following centrifugation, fractions were collected, and the density of each fraction was measured.
A portion of each fraction was separated by 10% SDS-PAGE, and SHIV antigens were detected by Western blotting, probing with anti-SIV monkey sera. (C) Env
is incorporated into chimeric lentivirus-like particles released into cell culture supernatant. Concentrated supernatant from cells mock transfected (lanes 1 and
2) or transfected with VEE RNA expressing Gag (lanes 3 and 4), Gag-Env (lanes 5 and 6), or Env-Gag (lanes 7 and 8) by transfection were immunoprecipitated
with anti-gp120 monoclonal antibody IgG1 b12 (lanes 2, 4, 6, and 8) or with anti-HA monkey serum (lanes 1, 3, 5, and 7). Viral particles were detected by Western
blotting with anti-Gag monoclonal antibody KK64.
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poration of Env into Gag-EnvCT or EnvCT-Gag particles (see
Fig. S2 in the supplemental material).
Morphogenesis of chimeric lentivirus-like particles in Vero
cells expressing Gag and Env. To assess the morphology of the
particles produced in Vero cells after expression of SHIV89.6P gag
and env from VEE RNA, ultrathin sections of transfected cells
were visualized by transmission electron microscopy. Mock-
transfected cells were included as a negative control, and cells
transfected with replicon RNA expressing Env served as a control
for the formation of Env microvesicles (Env MV) (25). Mock-
transfected cells were normal in morphology, with intact organ-
elles (Fig. 3A). Cells transfected with Env replicon RNA accumu-
lated significantly more mitochondria, and these appeared to be
deteriorating (data not shown). Significant accumulation of
smooth membrane vesicles was observed in Env-expressing cells
compared to cells that were mock transfected, and more vesicles
appeared to be released from the Env-expressing cells (compare
Fig. 3A and B). In contrast, cells transfected with VEE RNA ex-
pressing Gag alone accumulated large intracellular vacuoles that
periodically contained Gag VLPs (data not shown). However, the
majority of Gag VLPs produced were released from the plasma
membrane into the extracellular space (data not shown).
Vero cells transfected with Gag-Env and Env-Gag RNAs pro-
duced particles with the size and morphology of immature lenti-
virus particles. These were found primarily in the extracellular
space (Fig. 3C and D). The sizes of the particles ranged between
105 nm and 158 nm, with an average of 133.8  12.8 nm. Particles
budding from the plasma membrane into the extracellular space
suggested that assembly and budding of the particles occurred at
the plasma membrane in Vero cells. Some intracellular accumu-
lation of particles in vacuoles was observed in Vero cells trans-
fected with Env-Gag RNA; however, the majority of the particles
were released from the plasma membrane, as was observed for
expression of Gag alone. Some accumulation of intracellular ves-
icles also was observed in cells transfected with Gag-Env and Env-
Gag RNA; however, it was not to the extent observed in Env RNA-
transfected cells. More particles appeared to be produced in cells
transfected with Env-Gag RNA than with Gag-Env RNA, consis-
tent with a higher level of expression of Gag from the Env-Gag
construct than from the Gag-Env construct.
To verify that the particles produced in the Vero cells were
SHIV89.6P lentivirus particles containing both Gag and Env, ul-
trathin sections were double immunogold labeled with SIV Gag
p17 matrix (MA) monoclonal antibody visualized with a small
5-nm gold-labeled secondary antibody and labeled with HIV
gp120 b12 monoclonal antibody, followed by biotinylated sec-
ondary antibody and antibiotin conjugated to a large 20-nm col-
loidal gold bead (Fig. 3E to H). Minimal nonspecific background
was observed after mock-transfected cells were stained with the
primary and gold-conjugated secondary antibodies (Fig. 3E). Env
was detected in the cytoplasm, often near mitochondria and in-
tracellular vacuoles in cells transfected with replicon RNA ex-
pressing Env alone (Fig. 3F). Vero cells expressing Gag and Env
from VEE replicon RNA contained significant amounts of labeled
FIG 3 Production, assembly, and release of chimeric lentivirus-like particles
in Vero cells. Lentivirus particles are produced in cells expressing Gag and Env
from VEE-SHIV RNA. Vero cells were mock transfected or transfected with
Env, Gag-Env, or Env-Gag RNA. At 16 h posttransfection, cells were fixed,
immunolabeled, and prepared for visualization by transmission electron mi-
croscopy as described in Materials and Methods. (A and E) Mock-transfected
cells that did not express VEE nonstructural proteins or SHIV89.6P structural
proteins were normal in morphology and displayed minimal background lev-
els of immunogold labeling directed against SHIV89.6P Gag and Env antigens.
(B and F) Vero cells expressing Env accumulated smooth membrane vesicles in
the cell cytoplasm. Env was readily detectable in the cell cytoplasm by immu-
nogold labeling. (C, D, G, and H) Cells expressing Gag and Env produced
particles having the size and morphology of immature lentivirus particles that
budded from the plasma membrane. The particles contained SIV Gag (small
5-nm gold beads) and incorporated SHIV89.6P Env (large 20-nm gold beads).
Magnifications, 10,000 (A), 20,000 (B, C, D, and F), 25,000 (E), and
63,000 (G and H).
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Env that was not associated with particles (data not shown). Given
the fixation procedures inherent in immunogold labeling, it was
not possible to unequivocally observe whether Env in the cyto-
plasm was associated with intracellular membranes. Gag also was
detected in the cell cytoplasm, although not as readily detected as
Env (data not shown).
The lentivirus-like particles produced in Vero cells contained
both SIV Gag and HIV Env, demonstrating that both Gag and Env
are incorporated into the chimeric lentivirus-like particles. Simi-
lar amounts of Env appeared to be incorporated into particles
produced from Gag-Env and Env-Gag RNAs, suggesting that the
decreased expression of Env from Env-Gag RNA does not have an
effect on Env incorporation into particles (Fig. 3G and H).
Chimeric lentivirus-like particles nonspecifically incorpo-
rate VEE genomic and subgenomic RNA. In the absence of
genomic RNA, Gag utilizes cellular RNA to assemble particles (17,
43, 48). In addition, Semliki Forest virus replicon RNA is pack-
aged into retrovirus particles (28, 37). As alphaviruses inhibit host
transcription during replication, viral RNAs are the most abun-
dant intracellular RNAs, other than rRNA, during an alphavirus
infection. Hence, assembled Gag particles may nonspecifically in-
corporate viral RNA. In addition to genomic RNA, two sub-
genomic RNAs are produced from double-promoter VEE ge-
nomes (Fig. 4A). To assess the viral RNA content incorporated
into the chimeric lentivirus-like particles, a quantitative real-time
PCR assay was used to differentially detect genomic and sub-
genomic viral RNAs. Genomic RNA accounted for approximately
10% of the total viral RNA packaged into chimeric particles, while
subgenomic RNAs were the most abundant viral RNA species
(Fig. 4B). Surprisingly, the subgenomic RNA content of particle
preparations from Gag-Env RNA transfections was different from
the RNA content from Env-Gag RNA transfections. Particle prep-
arations produced from Gag-Env RNA incorporated significantly
more subgenome 2 (Env subgenome; 77% of total viral RNA) than
subgenome 1 (Gag-Env subgenome; 11% of total viral RNA). In
contrast, virus particles produced from Env-Gag did not incorpo-
rate subgenome 2 (Gag subgenome), and over 85% of total viral
RNA was subgenome 1 (Env-Gag subgenome) (Fig. 3). These re-
sults demonstrate that Gag nonspecifically incorporates viral RNA
during assembly into particles and that genomic replicon RNA
was packaged, albeit to relatively low levels.
Immature lentivirus-like chimeric particles infect cell lines
expressing human CD4 and coreceptors CCR5 and CXCR4.
NIH 3T3 cell lines that express human CD4 and CCR5 (NIH
3T3.CD4.CCR5) or that express CD4 and CXCR4 (NIH
3T3.CD4.CXCR4) were used to determine if the chimeric lentivirus-
like particles were infectious (Fig. 5). In addition, NIH 3T3 cells that
do not express CD4, CCR5, or CXCR4 were included as the parental
receptor negative cell line control. After infection of CD4 CCR5
(CXCR4)-expressing cells with SIV or HIV, Env is expressed at the
plasma membrane and catalyzes fusion with neighboring cells by en-
gaging CD4 and CCR5 (CXCR4) receptors to form syncytia. NIH
3T3.CD4.CCR5 cells (Fig. 5A) and NIH 3T3.CD4.CXCR4 cells (data
not shown) infected with Env-VRP or with Gag/Env chimeric
lentivirus-like particles formed syncytia. VEE nonstructural (repli-
case) proteins and SHIV structural proteins were consistently de-
tected in the syncytia by indirect immunofluorescence assay (IFA).
On occasion, viral structural and nonstructural proteins were de-
FIG 4 Chimeric particles contain VEE genomic and subgenomic RNA. (A) Schematics of the VEE-SHIV chimeric virus genomes and subgenomic RNAs
transcribed from genomic RNA. (B) Chimeric particles incorporate viral RNA. Encapsidated RNA was extracted from nuclease-treated particle preparations, and
the percentages of genomic and subgenomic viral RNA incorporated into chimeric lentivirus-like particles were determined by real-time PCR as described in
Materials and Methods. The results from three independent experiments were averaged, and the error bars indicate standard errors of the means. Subgenomic
RNA containing env was the most abundant viral RNA incorporated into the particles, whereas approximately 10% of the total viral RNA was genomic. NSP,
nonstructural protein.
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tected in a few individual cells surrounding the syncytia. Rare syncytia
were detected in NIH 3T3.CD4.CCR5 cells infected with Env mi-
crovesicles (MV) that were positive for VEE nonstructural antigens,
but these were significantly fewer than in cultures infected with Env-
VRP or chimeric lentivirus-like particles (Fig. 6 and data not shown).
In the parental cell line that lacks the appropriate receptors for infec-
tion by SIV or HIV, NIH 3T3 cells, syncytia were not observed after
infection with the chimeric lentivirus-like particles, and the monolay-
ers were indistinguishable from mock-infected cells (Fig. 5B). Al-
though syncytium formation was not observed in NIH 3T3 cells, VEE
nonstructural protein expression was detected in cells infected with
Env-VRP, which infect using cellular receptors specific for VEE. This
confirms that 3T3 cells are capable of supporting VEE genomic RNA
replication. These results demonstrate that the immature lentivirus-
like chimeric particles were capable of infecting cells expressing hu-
man CD4 and CCR5/CXCR4 in a receptor-dependent manner and
were capable of directing RNA replication. In addition, Env expressed
from VEE RNA was functional, as shown by the formation of syncytia
only when the target cells displayed CD4 and CCR5 or CXCR4. Chi-
meric lentivirus-like particles were also able to infect T cell lines
SupT1 and CEMX174 (see Fig. S4 in the supplemental material) and
monocyte cell lines THP-1 and U937 (data not shown).
A plaque assay to titrate chimeric virus infectivity was devel-
oped based on syncytium formation (30, 45). Syncytia were enu-
merated as plaques, and titers were determined as in a standard
plaque assay (Fig. 6B). To validate this methodology of titration,
the titer of Env-VRP using a standardized indirect immunofluo-
rescence assay on BHK cells (38) was directly compared to the titer
determined by syncytium formation on NIH 3T3.CD4.CCR5 cells
and on U87.CD4.CXCR4 cells (Fig. 6A). The titer of Env-VRP on
BHK cells averaged to 1.01  108  2.99  107 IU/ml and was
similar to the titer determined by syncytium formation on NIH
FIG 5 Chimeric lentivirus-like particles are infectious. NIH 3T3.CD4.CCR5 cells (A) or NIH 3T3 cells (B) were mock infected, infected with Env-VRP, or
infected with chimeric lentivirus-like particles. At 18 hpi, the cells were fixed, permeabilized, and incubated with antiserum from mice infected with VRP-Gag
that contains antibodies against the VEE nonstructural proteins and SIV Gag. Expression of viral proteins was visualized by indirect immunofluorescence. (A)
Chimeric particles infect coreceptor-positive cells. RNA replication and expression of gp160 Env from VEE RNA resulted in the formation of syncytia in the cell
monolayers that expressed VEE nonstructural and SHIV89.6P structural proteins. (B) Chimeric particles do not infect cells that lack CD4 and CCR5. Env-VRP
infection and gene expression were detected in the cell monolayers; however, syncytium formation was not detected in the absence of CD4 and CCR5 receptors.
FIG 6 Development of a plaque assay based on syncytium formation to quan-
titate chimeric virus infectivity. Formation of syncytia on 3T3.CD4.CCR5 or
U87.CD4.CXCR4 cell monolayers was used as the basis to develop quantitative
assays for biologically active chimeric particles as described in Materials and
Methods. (A) The titer of Env-VRP determined by standard indirect immu-
nofluorescence assay on BHK cells compared to the titer determined by syn-
cytium formation in 3T3.CD4.CCR5 and U87.CD4.CXCR4 cell lines to vali-
date the plaque assay. (B) Representative plaque assay to determine titers of
chimeric virus particle preparations. U87.CD4.CXCR4 cell monolayers were
infected with 2-fold serial dilutions of chimeric particles or Env microvesicles
produced in cells transfected with Env-expressing replicon RNA in the absence
of Gag (EnvMV). Syncytia were detected by immunostaining with HIV Ig and
were enumerated as plaques, as described in Materials and Methods.
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3T3.CD4.CCR5 cells (1.21  108  5.24  107) and on
U87.CD4.CXCR4 cells (1.26  108  1.55  107). The titers of
chimeric particles ranged from approximately 1  103 to 1  104
IU/ml based on this assay (Table 1). A representative assay is
shown in Fig. 6B. To control for the detection of infectivity medi-
ated by microvesicles that are produced when Env is expressed in
cells, we transfected Vero cells with VEE replicon RNA expressing
SHIV89.66P Env and purified the microvesicles using the same
procedures as described in Materials and Methods for VRP and
chimeric particles. Sporadic appearance of syncytia did occur;
however, the quantitative titer was below the limit of detection of
the assay (Fig. 6B). Therefore, Env microvesicles do not contribute
to the overall titer of chimeric lentivirus particle preparations. The
titers of virus preparations produced from Gag-Env and Gag-
EnvCT were also similar. Although the Env cytoplasmic tail
truncation increased incorporation of Env into chimeric particles,
a significant increase in viral titer was not observed.
Infection of cell lines with the chimeric particles is produc-
tive. To confirm that progeny chimeric lentivirus-like particles
were assembled after infection of NIH 3T3.CD4.CCR5 cells with
chimeric viruses, the syncytia that formed after infection and the
extracellular space around syncytia were visualized by TEM. NIH
3T3.CD4.CCR5 cells were mock infected, infected with Env-VRP
as a control for Env microvesicles that form from expression of
Env, or infected with chimeric lentivirus-like particles. The syncy-
tia that formed after infection were embedded and cut into ultra-
thin sections for TEM as described in Materials and Methods (Fig.
7A to C). In addition, sections were double immunogold labeled
as described in the legend of Fig. 3 and in Materials and Methods
to verify that both Gag and Env were incorporated into progeny
particles produced after infection with the chimeric lentivirus-like
particles (Fig. 7D to H). Mock-infected cells were normal in mor-
phology, did not contain large vacuoles, and displayed minimal
background staining with antibody-colloidal gold bead com-
plexes (Fig. 7D and data not shown). In contrast to the Vero cells
that were transfected with chimeric virus genomic RNA (Fig. 3),
NIH 3T3.CD4.CCR5 cells infected with Env-VRP or with chime-
ric lentiviral particles accumulated large perinuclear vacuoles (Fig.
7A to C). Vacuoles that formed in the Env-VRP-infected cells were
either empty (data not shown) or contained some debris (Fig. 7A).
Vacuoles containing microvesicles were also observed (data not
shown). Vacuoles that formed in the chimeric lentivirus-like
particle-infected cells contained immature lentivirus-like parti-
cles that were labeled with SIV Gag and HIV Env gold-conjugated
antibodies (Fig. 7B, C, and F to H). More particles were present in
the vacuoles of cells that were infected with Env-Gag chimeric
particles than in the vacuoles of cells that were infected with Gag-
Env chimeric particles (Fig. 7, compare C to B and F to H). Chi-
meric lentivirus-like particles were also observed in the extracel-
lular space in cells infected with Gag-Env-derived particles but not
in the cells infected with Env-Gag-derived virus (Fig. 7B and H).
These experiments demonstrate that chimeric lentivirus-like
particles were able to infect susceptible cells, replicate the chimeric
viral genomic RNA, and express Gag and Env, leading to the as-
sembly and release of a second generation of progeny chimeric
particles. However, further passage resulted in the loss of detect-
able chimeric particle infectivity.
Modifications to the chimeric VEE-SHIV virus genomes for
improved propagation of chimeric lentivirus-like particle vac-
cines. In the chimeric lentivirus-like particle preparations, large
numbers of physical particles appeared to be produced from Vero
cells, yet the specific infectivities of these preparations were low
when assessed in murine and human cell lines expressing CD4 and
CCR5/CXCR4 coreceptors. We hypothesized that the immature
form of Gag particles may not efficiently uncoat and release the
chimeric particle genome after infection of susceptible cells. In
addition, since only 10% of total RNA in particle preparations was
genomic, the specificity of genome packaging into the chimeric
particles may be too low to sustain propagation. Therefore, a
modified SIV protease was added to the chimeric particle genome,
and, in parallel, the gag gene was modified to specifically incorpo-
rate the chimeric virus genome into the virus vaccine particles.
Maturation of chimeric lentivirus-like particles. Protease-
dependent, lentiviral particle maturation occurs either during or
after budding from the cell membrane and is required for lentivi-
rus particles to become infectious (24). Protease (PR) is encoded
in the pol open reading frame immediately downstream from gag
and is expressed as polyprotein Gag-Pol following ribosomal
frameshifting. Ribosomal frameshifting occurs approximately 5
to 10% of the time, and the ratio of Gag to Gag-Pol is approxi-
mately 20:1 in lentivirus-infected cells (21). The ratio of Gag to
Gag-Pol precursor proteins in the assembling virion is reflective of
the levels of proteins expressed in the cell (46). Proteolytic pro-
cessing of Gag and Gag-Pol precursors is tightly regulated and
initiates after immature particles have assembled. Overexpression
of Gag-Pol in several vector expression systems results in prema-
ture protease activation and cleavage of p55 Gag and p160 Gag-
Pol, which prevents assembly and release of particles (23, 32).
Mutation of HIV-1 protease at codon 28 in the active-site triad
from an alanine to serine (A28S) reduced proteolytic activity by
approximately 50-fold without significant effects on substrate
binding (20).
To improve the infectious titer of the chimeric lentivirus-like
particles, chimeric viral genomes that incorporate the SIV pro-
tease for cleavage of Gag and particle maturation were con-
structed. The natural frameshift site in SHIV89.6P was main-
tained, and protease was expressed from the 1 reading frame
relative to the Gag open reading frame. Ten N-terminal amino
acids from reverse transcriptase (RT) were added to the C termi-
nus of GagPR to maintain the protease cleavage site and for regu-
lation of the polyprotein processing cascade. Complete intracellu-
lar processing of Gag was observed after expression of SHIV89.6P
GagPR from VEE replicon RNA in Vero cells, abrogating the for-
mation of particles. Micromolar concentrations of the protease
inhibitor saquinavir rescued the assembly and release of Gag par-
ticles into the supernatants. Western blot analysis indicated that
the particles released in the presence of saquinavir contained the
processed forms of Gag (data not shown). Therefore, the attenu-
ating mutation of codon 28 from alanine to serine was introduced
TABLE 1 Summary of the range of titers obtained from chimeric
lentivirus-like particle preparations
Virus Titer (PFU/ml)a
Gag-Env 1  103-1  104
GagPR(A28S)-Env 1  104-1  105
GagNCVEE Csub-Env 1  104-1  105
GagPR(A28S)NCVEE Csub-Env 1  105-1  106
a Viral titer determined by plaque assay.
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into VEE plasmids encoding SIV GagPR-Env. Viral RNA was
transfected into Vero cells, and gene expression was analyzed by
Western blotting. Gag was extensively processed intracellularly
after expression of wild-type GagPR-Env, and significantly fewer
particles were assembled or released into the cell culture superna-
tant (Fig. 8, lane 2). However, the protease mutation A28S atten-
uated proteolytic cleavage of Gag intracellularly, and particles
containing processed forms of Gag were found in the culture su-
pernatant. The identity of the processed forms of Gag was con-
firmed by Western blotting, probing with monoclonal antibodies
to p17 matrix and p27 capsid (Fig. 8). In contrast to the concen-
trated supernatants from transfection with Gag-Env RNA (Fig. 2
and 8, lane 1), the presence of Env was detected very well in the
concentrated supernatants when it was expressed from GagPR-
Env (Fig. 8, lane 2). To assess the morphology of the particles
produced from Gag and a truncated Pol protein containing the
A28S mutation, ultrathin sections of transfected cells were visual-
ized by transmission electron microscopy. Truncation of Pol did
not result in defects in virion assembly, and the particles produced
retained the morphology lentiviruses (see Fig. S5 in the supple-
mental material).
The infectivity of Gag-Env, GagPR-Env, and GagPR(A28S)-
Env chimeric particle preparations was quantified by plaque assay,
and the Gag content within virus preparations was measured by
ELISA to determine if the inclusion of protease improved the spe-
cific infectivity of chimeric virus vaccine candidates. Although the
viral titers and Gag content varied from experiment to experi-
ment, the results of multiple experiments demonstrated that the
inclusion of protease improved the overall infectivity of chimeric
virus vaccines, with titers ranging from 1 to 2 logs higher than for
Gag-Env chimeric virus. GagPR(A28S)-Env consistently reached
higher titers than GagPR-Env and Gag-Env virus and ranged from
1  104 to 1  105 (Table 1). Since the p27 ELISA used in these
experiments specifically recognized highly processed forms of
Gag, we were unable to accurately determine the specific infectiv-
ity of the virus preparations due to the different extents of Gag
processing inherent in the different chimeric virus vaccine con-
structs.
To determine if the addition of protease and particle matura-
tion improved the ability of chimeric virus vaccine particles to
propagate, particles produced from Gag-Env, GagPR-Env, and
the mutant GagPR(A28S)-Env genomes were passaged on NIH
3T3.CD4.CCR5 cells. Twenty-four hours after infection of NIH
3T3.CD4.CCR5 cells with chimeric virus particles Gag-Env,
GagPR-Env, and the mutant GagPR(A28S)-Env, syncytia devel-
oped in the cultures. Supernatants from the initial infection were
FIG 7 Syncytium formation in 3T3.CD4.CCR5 cells infected with chimeric
lentivirus-like particles or with Env-VRP. 3T3.CD4.CCR5 cells were mock
infected, infected with Env-VRP, or infected with chimeric lentivirus-like par-
ticles. At 16 hpi, cells were prepared for visualization by TEM (A to C) or immu-
nogold labeled prior to TEM (D to H) as described in Materials and Methods. (A
to C) Thin-section electron micrographs depicting the morphology and contents
of syncytia that formed in 3T3.CD4.CCR5 monolayers after infection with
Env-VRP or with chimeric lentivirus-like particles (20,000 magnification).
(D to H) Electron micrographs of thin sections that were immunogold labeled
with SIV Gag (small 5-nm gold beads) and HIV Env (large 20-nm gold beads)
as described in Materials and Methods. (D) Minimal background labeling was
detected in mock-infected 3T3.CD4.CCR5 cells labeled with Gag and Env
antibody conjugated to gold beads. Syncytia in 3T3.CD4.CCR5 cells infected
with Env-VRP accumulated large intracellular vacuoles (A and E). Env was
readily detectable in the cell cytoplasm by immunogold labeling. Syncytia in
3T3.CD4.CCR5 cells infected with chimeric lentivirus-like particles also accu-
mulated large vacuoles that contained progeny chimeric particles that were
positive for SIV Gag and HIV Env (B, C, F, G, and H). Occasionally, Gag-Env
chimeric particles were released into the extracellular space (B and H). Mag-
nifications, 20,000 (A to C, E), 25,000 (D), and 40,000 (F to H).
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harvested and passaged onto fresh NIH 3T3.CD4.CCR5 cell
monolayers at a 1:10 dilution as described in Materials and Methods.
As observed before, supernatants from Gag-Env particle infection
were not capable of a second round of propagation. However, cul-
tures that were infected with GagPR-Env and GagPR(A28S)-Env vi-
ruses had detectable syncytia within 24 h, suggesting an improvement
in the ability of these chimeric particles to propagate. The superna-
tants from the second passage were harvested and used to infect fresh
monolayers of NIH 3T3.CD4.CCR5 cells at a 1:10 dilution. No syn-
cytia were readily observed in the passage 3 cultures. Therefore, in-
clusion of the modified SIV protease improved the ability of the chi-
meric virus particles to propagate in cell culture but was insufficient
to sustain long-term propagation.
Incorporation of a putative VEE genomic RNA binding do-
main into the chimeric virus vaccine particles. In the absence of
specific viral genomic RNA encapsidation signals, subgenomic
RNA accounted for the majority of the viral RNA incorporated
into particles (Fig. 4). In an alphavirus-infected cell, subgenomic
RNA is produced in molar excess over genomic RNA. Specific
genomic RNA encapsidation signals have been identified in the
NSP1 and NSP2 regions of related alphaviruses, Sindbis virus (52)
and Ross River Virus (13), that are recognized by an RNA binding
domain in the capsid protein (15). The VEE capsid fragment,
amino acids 75 to 132, by analogy with Sindbis virus, may bind
specifically to the VEE genomic RNA in an unidentified replicase
region (51).
The NC domain of Gag was replaced with a fragment of the
VEE capsid (VEE C) protein analogous to that of the Sindbis virus
capsid fragment RNA binding domain, while maintaining SIV
protease cleavage sites between p2 VEE C and VEE C2p2. The
modified chimeric virus genome, GagNCVEE Csub-Env, was
transfected into Vero cells, and gene expression was analyzed by
Western blotting (Fig. 8A, lane 4). Replacement of the NC domain
of Gag with the VEE C domain decreased the overall yield of chi-
meric lentiviral physical particle production (Fig. 8B, lane 4);
however, the titer of infectious particles increased by 1 log com-
pared to Gag-Env and ranged from 1  104 to 1  105 (Table 1).
The ability of GagNCVEE Csub-Env to propagate was evalu-
ated by serial passage in NIH 3T3.CD4.CCR5 cells as described
above and in Materials and Methods. Although the viral titers
improved, after two rounds of serial passage, GagNCVEE
Csub-Env also lost the ability to propagate.
To determine if the inclusion of protease and the inclusion of a
putative VEE RNA binding domain together could enhance the
ability of chimeric lentivirus-like virus particles to propagate, the
VEE capsid substitution was placed into the GagPR(A28S)-Env
genome to create GagPR(A28S)NCVEE Csub-Env. Viral RNA
was transfected into Vero cells, and gene expression and particle
production were analyzed by Western blotting (Fig. 8, lane 5).
Protease properly cleaved GagPR(A28S)NCVEE Csub-Env, in-
dicating that the replacement of the NC domain of Gag with the
VEE C binding domain did not result in defective or aberrant
cleavage (Fig. 8, compare lane 3 to lane 5). Also, the inclusion of
PR appeared to facilitate assembly and release of chimeric
GagPRNCVEE Csub-Env particles, as evidenced by the signif-
icantly increased amount of unprocessed p56 Gag, p27 capsid, and
other processed forms of Gag in the concentrated supernatants
after expression of GagPRNCVEE Csub-Env genomes (Fig. 8B,
lane 5) compared to the amount of unprocessed Gag in the con-
centrated supernatants from GagNCVEE Csub-Env (Fig. 8B,
lane 4).
The growth rate of GagNCVEE Csub-Env was compared to
that of GagPR(A28S)NCVEE Csub-Env to determine if the in-
clusion of SIV protease improved replication of GagNCVEE
Csub-Env. NIH 3T3.CD4.CCR5 cells were infected with 100 infec-
tious units (IU) of GagNCVEE Csub-Env and GagPR(A28S)
NCVEE Csub-Env chimeric lentivirus-like particles, and viral
growth was measured over time as described in Materials and
Methods. Replication of GagNCVEE Csub-Env was detected at
12 hpi and remained steady out to 72 hpi. In contrast, replication
FIG 8 Expression of SHIV89.6P structural proteins from modified chimeric virus genomes. Vero cells were mock transfected (M) or transfected with Gag-Env
(lanes 1), GagPR-Env (lanes 2), GagPR(A28S)-Env (lanes 3), GagNCVEE Csub-Env (lanes 4) and GagPR(A28S)NCVEE Csub-Env (lanes 5) RNA. At 24 h
posttransfection, cell lysates were prepared (left panel), and cell culture supernatants were clarified and concentrated through a 20% sucrose cushion (right
panel). Samples were separated by 10% SDS-PAGE, and SHIV antigens were detected by Western blotting using monoclonal antibodies to SIV Gag and HIV Env,
as indicated to the left of the panels. Conc, concentrated.
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of GagPR(A28S)NCVEE Csub-Env steadily increased through
60 hpi, suggesting that the two modifications together increased the
replication capacity of chimeric lentivirus-like particles (Fig. 9A).
The ability of GagPR(A28S)NCVEE Csub-Env to propagate
was evaluated by serial passage on NIH 3T3.CD4.CCR5 cells as
described above. GagPR(A28S)NCVEE Csub-Env continued
to propagate after five serial passages in NIH 3T3.CD4.CCR5 cells.
At 48 h postinfection of passage 3, viral CPE measured by syncy-
tium formation was increased compared to the amount of passage
2. Subsequent passages also showed increasing amounts of syncy-
tium formation at 48 h postinfection. To determine if serial pas-
sage in NIH 3T3.CD4.CCR5 resulted in increased replication of
GagPR(A28S)NCVEE Csub-Env, as suggested by increasing
levels of CPE after sequential passages, the growth rate of virus
harvested after passage 1 was directly compared to the growth rate
of virus harvested at passage 5. NIH 3T3.CD4.CCR5 cells were
infected with 100 IU of GagPR(A28S)NCVEE Csub-Env pas-
sage 1 virus and GagPR(A28S)NCVEE Csub-Env passage 5 vi-
rus, and viral replication was measured over time as described in
Materials and Methods (Fig. 9B). Replication of passage 1 virus
continued to steadily rise through 60 hpi, as shown in Fig. 9A.
However, viral replication of passage 5 virus continued to rise
through 72 hpi and had a 1-log higher titer than passage 1 virus,
suggesting that serial passage selected for increasingly fit viruses.
The addition of SIV protease and a putative VEE RNA binding
domain together was required for sustained propagation of VEE-
SHIV chimeric virus vaccine particles.
DISCUSSION
This report describes the development of a novel chimeric live
attenuated virus vaccine candidate combining genome ele-
ments from distinctly different virus families. Lentiviral struc-
tural proteins expressed from chimeric alphavirus genomes
self-assembled into lentivirus-like particles that incorporated
sufficient amounts functional Env trimers for infectivity and
contained the chimeric genomic RNA. Infection of susceptible
cells with the chimeric particles was productive, resulting in the
uncoating of chimeric viral genomic RNA in the cell cytoplasm,
RNA replication, expression of VEE replicase proteins and len-
tivirus structural proteins, and the assembly and release of
propagation-competent progeny chimeric virus particles. The
chimeric virus vaccine prototype described here differs from
chimeric live attenuated virus vaccines that express heterolo-
gous structural proteins from an additional gene cassette
placed into the virus genome, and it differs from chimeric live
attenuated virus vaccines that express heterologous proteins
from a related virus in the same virus family, such as chimeric
flavivirus vaccines.
Although recombinant viral vectors expressing SIV/HIV im-
munogens induce immune responses that result in reduction of
viral loads following challenge, consistent and strong protection
against infection has yet to be achieved. Only live attenuated ver-
sions of SIV have shown protection in rigorous macaque challenge
models, but these are considered unsafe for progression to human
clinical trials. The chimeric virus approach is designed to mimic a
live attenuated lentivirus vaccine for the induction of a robust,
balanced immune response that is safe and protective and to have
the potential to overcome several limitations of live attenuated
lentivirus vaccines: (i) replication is self-limiting due to interferon
sensitivity, (ii) RNA replication occurs in the cell cytoplasm and
infection is nonpersistent, (iii) viral replication is attenuated due
to the addition of the second subgenomic promoter, and (iv)
propagation is attenuated due to the chimeric nature of the virus
genome.
Self-replicating SHIV89.6P particles derived from chimeric
VEE-SHIV genomes were produced after RNA transfection of ro-
dent (BHK), murine (3T3), and primate (Vero) cells. Defects in
SIV assembly and release were not observed in BHK and 3T3 cells
FIG 9 Infectivity is enhanced by viral passage of VEE/SHIV GagPR(A28S)NC
VEE Csub-Env chimeric viruses. (A) Growth curve of chimeric viruses following
one passage in NIH 3T3.CD4.CCR5 cells. NIH 3T3.CD4.CCR5 cells were infected
with 100 IU of chimeric particles. Samples were taken for 72 h at 12-h increments
to determine the progeny titer. The titer of the virus is shown as the total
number of infectious units/culture at each time point. Black squares are
GagPR(A28S)NCVEE Csub-Env, and gray circles are GagNCVEE Csub-
Env. (B) Growth of unpassaged GagPR(A28S)NCVEE Csub-Env chimeric vi-
rus was compared to growth of GagPR(A28S)NCVEE Csub-Env chimeric virus
isolated after five sequential passages in NIH 3T3.CD4.CCR5 cells. NIH
3T3.CD4.CCR5 cells were infected with 100 IU of passage 1 or passage 5
GagPR(A28S)NCVEE Csub-Env chimeric viruses. Samples were taken for 72 h
at 12-h increments to determine the progeny titer. The titer of the virus is shown as
the total number of infectious units/culture at each time point. Diamonds are
passage 1 virus, and squares are passage 5 virus.
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when results were directly compared to particle production in
Vero cells although particle production was somewhat reduced in
3T3 cells. Efficient assembly and release from rodent or murine
cells may be due to higher levels of Gag expression from VEE RNA
which overcome potential blocks to lentivirus assembly and re-
lease. In addition, exchanging SIV MA for HIV MA enhances as-
sembly of HIV in murine cells, suggesting that SIV Gag may not be
as restricted for assembly in murine cells compared to HIV Gag
(6). The lower yields of chimeric particles released from 3T3 cells
may also be due to assembly and budding into intracellular vacu-
oles rather than from a defect in expression and assembly (Fig. 8).
Although we did not observe significantly large amounts of
Env incorporated into VEE-SHIV chimeric particles, a sufficient
level of functional trimers was present to mediate binding and
entry, as evidenced by the ability of VEE-SHIV chimeric particles
to infect susceptible cells (Fig. 5). To improve incorporation of
Env into VEE-SHIV chimeric particles, the cytoplasmic tail was
truncated. However, increased incorporation of Env into chime-
ric lentivirus-like particles did not correlate with increased titers
of virus (see Fig. S2 in the supplemental material). This is consis-
tent with the observation that one HIV Env trimer is sufficient to
mediate binding and entry (57). Maturation cleavage of gp160
Env to gp120 and gp41 appeared to be inefficient. This may be due
to overexpression of gp160 from VEE RNA, limiting the availabil-
ity of furin protease in the Golgi compartment that is not observed
when Env is expressed from lentiviral message RNA. Alternatively,
disruption of normal cellular secretory and protein processing
pathways from VEE RNA replication may have contributed to the
inefficient maturation cleavage of Env.
In the absence of specific RNA packaging signals within the
chimeric virus genome, genomic RNA was incorporated into chi-
meric lentivirus-like particles at low levels, and subgenomic RNA
accounted for the majority of the incorporated viral RNA. Sub-
genomic RNA is produced to higher levels than genomic RNA in
alphavirus-infected cells (44, 50) and is consistent with Gag pro-
miscuously packaging the most abundant RNA species for particle
assembly. In addition, VEE-SHIV genomic RNA is significantly
longer than lentiviral genomic RNA, and it may not be as effi-
ciently incorporated into assembling particles as the alphaviral
subgenomic RNAs. It was interesting that the subgenomic RNA
contents of virus vaccine preparations produced from Gag-Env
and Env-Gag were different. Incorporation of subgenomes may
not be based solely on the size of the RNA since over 85% of viral
RNA incorporated into Env-Gag particles was subgenome 1, and
over 75% of viral RNA incorporated into Gag-Env particles was
subgenome 2. Results from these experiments suggest that either
subgenomic RNAs containing the env coding sequence were pref-
erentially incorporated into chimeric vaccine particles or that gag
coding sequences were excluded. Sequences in the 5= terminus of
Gag may contribute to the packaging of HIV genomic RNA into
assembling virions (27, 33). In lentivirus genomes, these se-
quences are in the context of the 5= untranslated region (UTR) and
 packaging signal, which is not present in alphavirus subgenomic
RNAs encoding Gag. The RNA structure of HIV genomic RNA is
most likely different from the RNA structure of alphavirus sub-
genomic RNA encoding Gag; therefore, sequences in Gag that
contribute to packaging HIV genomic RNA may not be in the
right structural conformation to enhance packaging of sub-
genomic RNAs encoding Gag. Alternatively, the 5= end of Gag
may contain signals sufficient for encapsidation of subgenomic
RNA if gag is in the first position. However, gag in the second
position may not be in the right conformation to promote encap-
sidation.
Two modifications were introduced into the prototype Gag-
Env chimera which increased the specific infectivity of the chime-
ric virus particles. First, a mutated protease was inserted in its
normal relationship to Gag to promote particle maturation. Sec-
ond, a putative VEE genome packaging element, derived from the
VEE capsid protein, was added to the chimera in place of NC.
Although the effects of adding the VEE capsid fragment at differ-
ent sites in Gag were evaluated, this modification was the best
choice in terms of both increased specific infectivity and place-
ment of the protease at its normal site.
The chimeric virus vaccine particles produced after expression
of unmodified Gag and Env from VEE RNA were morphologically
similar to immature lentivirus particles, and Gag was incorpo-
rated into them as the uncleaved precursor. Remarkably, VEE-
SHIV chimeric virus particles did not require SIV protease-
mediated particle maturation in order to be at least minimally
infectious. Lentivirus particle maturation involves the cleavage of
the Gag polyprotein, resulting in a structural rearrangement of the
viral particle to form a condensed core around the lentiviral
nucleocapsid-RNA complexes, and is required for lentivirus in-
fectivity (24, 53). VEE-SHIV chimeric virus vaccine particles were
able to release viral RNA into the cell cytoplasm and replicate,
suggesting that cleavage maturation is not an absolute require-
ment for chimeric particle infectivity. However, the inclusion of
SIV protease in the VEE-SHIV chimeric virus vaccine enhanced
the infectivity of the particles, most likely by promoting particle
maturation. Cleavage of Gag may have resulted in destabilization
of the capsid shell, facilitating release of the RNA genome for more
efficient replication. In addition, the inclusion of protease ap-
peared to enhance the incorporation of Env into the chimeric
virus particles. The matrix domain of Gag is reported to recognize
the cytoplasmic tail domain of Env for inclusion in budding par-
ticles (12, 16). Cleavage of Gag may have either exposed the Env
binding domain or altered its conformation to facilitate inclusion
of Env into the chimeric virus particles. Addition of the A28S
mutation to attenuate protease activity decreased incorporation
of Env to levels observed in the absence of protease (Fig. 8). This
further suggests that cleavage of Gag may have enhanced Env in-
corporation into chimeric particles. Curiously, increased Env in-
corporation did not correlate with improved infectivity of the chi-
meric virus preparations since we observed higher titers of
GagPR(A28S)-Env particles than the titers observed for GagPR-
Env particles, and increased incorporation of Env by truncating
the cytoplasmic tail did not correlate with improved titers com-
pared to those of Gag-Env particles.
Although incorporation of putative genome packaging do-
mains and modified protease independently improved the specific
infectivity of chimeric virus particle preparations, both improve-
ments were required for VEE-SHIV chimeric virus vaccine parti-
cles to propagate efficiently in cell culture. After several passages,
the growth of the vaccine particles improved, suggesting that it is
possible to evolve the vaccine particles for improved growth prop-
erties. Selection for chimeric virus particle growth in primate cell
lines expressing the coreceptors may be advantageous for further
improvement of the VEE-SHIV chimeras, prior to evaluating their
efficacy as vaccine candidates in nonhuman primates.
The development of a live attenuated virus vaccine technology
Replicating Lentivirus-Like Particle
January 2012 Volume 86 Number 1 jvi.asm.org 259
by creating chimeric viruses from heterologous virus families has
several vaccine, therapeutic, and research applications. This tech-
nology may be beneficial for the creation of other live virus vac-
cines that may be considerably safer than live attenuated versions
of viral pathogens such as rotavirus, flaviviruses, and filoviruses.
Microbial or cancer immunogens may be incorporated into the
chimeric virus particles for the development of cognate vaccines,
or they may be used as directed delivery vehicles for therapeutic
applications. As a research reagent, chimeric viruses may be used
to study the role of structural proteins in viral attachment, entry
and uncoating, and assembly, separate from their function in rep-
lication. Chimeric particles may also be useful reagents for gener-
ating antibodies against pathogens for diagnostic or passive im-
munization purposes or may be useful for the identification of
neutralizing antibodies from serum.
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